Apellis Pharma has become the first company to claim FDA approval for a drug to treat geographic atrophy (GA), a sight ... and retinal pigment epithelial (RPE) cells, the central portion of ...
Hosted on MSN11mon
Eyestem to initiate human trials for its therapy to treat eye disorderto commence human trials for Eyecyte RPE. According to the company’s press statement, the therapy is aimed at combating geographic atrophy arising from dry age-related macular degeneration (AMD).
The phase 1b trial will enrol patients with geographic atrophy secondary to age-related ... of photoreceptors and retinal pigment epithelial (RPE) cells in the central portion of the retina ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback